Multiples PE-led consortium invests $88 mn in BDR Pharma
- The consortium comprised the investment arm of Times Group, QRG Invest (Havells Family Office), and high net worth individuals Nishant Agarwal of Avighna Group, and Mallika Srinivasan of TAFE
NEW DELHI: Private equity firm Multiples Alternate Asset Management Pvt. Ltd-led consortium has invested ₹685 crore, or around $88 million, in drugmaker BDR Pharmaceuticals International for a 9.3% stake.
The investors in the consortium include the investment arm of Times Group, QRG Invest (Havells Family Office), and high net worth individuals Nishant Agarwal of Avighna Group, and Mallika Srinivasan of TAFE, said Multiples in a statement.
Mumbai-based BDR Pharmaceuticals will use the capital to boost its research and development capabilities and expand its manufacturing capacity. The company also aims to selectively scout for acquisition opportunities.
BDR Pharmaceuticals, part of the BDR group, was founded in 2003 by Dharmesh Shah. The company manufactures active pharmaceuticals ingredients (API) or bulk drugs. The group also has another entity BDR Lifesciences Pvt. Ltd, which is involved in formulation manufacturing. For drug development, the group focuses on four specialised therapeutic segments -oncology, critical care, gynaecology and neurology.
Manish Gaur, managing director and head of healthcare at Multiples, said in a statement, that BDR Pharmaceuticals has built a strong business in India as well as overseas markets.
“Healthcare, as an industry is highly promising in India and Multiples, brings strong sector expertise with investments in companies across the value chain... We will continue to explore partnering with promising enterprises in the healthcare industry,” added Gaur.
Multiples, founded in 2009 by former ICICI Venture managing director and CEO Renuka Ramnath, announced the final close of its third fund at $680 million last year.
Its first investment in the healthcare space was in Bengaluru-based Vikram Hospital, which was acquired by multispecialty chain Manipal Hospitals last year. A person familiar with the development had told VCCircle that Multiples made around 2.5 times on its equity investment from Vikram Hospital.
The private equity firm later made pharmaceuticals investments in contract development and manufacturing firm Encube Ethicals Pvt. Ltd and in Natco Pharma. In May last year, a consortium led by Multiples agreed to acquire an animal health business from a wholly owned unit of Cadila Healthcare Ltd (brand name Zydus Cadila) for ₹2,921 crore ($397 million).
Multiples' bets outside the healhtcare and pharmaceutcicals include fantasy gaming firm Dream11, logistics platform Delhivery, multiplex chain PVR, big data startup Quantiphi, and human resources technology company PeopleStrong.
Last year, Multiples also made investments in meat brand Licious and customer analytics and cross-channel engagement platform MoEngage.
Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
MoreLess
First Published:17 May 2022, 01:10 PM IST
- Top Gainers
- Top Losers
- 52 Week High